首页> 外文期刊>Journal of population therapeutics and clinical pharmacology >Patterns of Oral Anticoagulants Use in Atrial Fibrillation
【24h】

Patterns of Oral Anticoagulants Use in Atrial Fibrillation

机译:房颤使用口服抗凝剂的方式

获取原文
           

摘要

Background Novel oral anticoagulants are available for the management of atrial fibrillation and are considered more convenient to use than warfarin. Objective The main objective of this study was to describe patterns of oral anticoagulant use in the 6 months period following the availability of dabigatran at our hospital. Methods A cross-sectional study was conducted in a single University hospital in the province of Québec, Canada. Medical records of subjects on oral anticoagulants for atrial fibrillation that were hospitalized between October 1 st , 2011 and March 31th, 2012 were reviewed. Type of use (prevalent, incident and switch) and patient's characteristics of warfarin and dabigatran users were compared using Chi-squared and T-tests. Results In the 6-month period following dabigatran availability in the hospital, 59 patients (13%) were on dabigatran and 388 (87%) on warfarin. Mean CHADS 2 score, mean age and mean number of chronic medications were lower in the dabigatran group. The percentage of patients with coronary artery disease was lower and renal function was higher in the dabigatran group. Conclusion Dabigatran use remained low in the first 6 months period following the approval of dabigatran at our hospital, which could be explained by limited data on the efficacy and safety of this agent in subjects with multiple comorbidities.
机译:背景技术新型口服抗凝剂可用于房颤的治疗,并且被认为比华法林更方便使用。目的这项研究的主要目的是描述达比加群在我院可用后的六个月内口服抗凝药的方式。方法在加拿大魁北克省一家大学医院进行横断面研究。回顾了2011年10月1日至2012年3月31日住院的口服抗凝剂治疗房颤的病历。使用卡方检验和T检验比较了华法林和达比加群使用者的使用类型(普遍,事件和转换)以及患者的特征。结果在医院中达比加群使用6个月后,达比加群用药59例(13%),华法林用388例(87%)。达比加群组的平均CHADS 2评分,平均年龄和长期用药的平均数较低。达比加群组冠心病患者的百分比较低,肾功能较高。结论在我们医院批准达比加群后的头6个月,达比加群的使用率仍然很低,这可由该药对多种合并症患者的疗效和安全性有限的数据来解释。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号